Publications by authors named "Eric Gauthier"

Claim this Profile
C
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani, Eric Gauthier

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.
Richard S Finn, Hope S Rugo, Javier Cortes, Sibylle Loibl, Grace Foley, Eric Gauthier

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.
Debu Tripathy, Joanne L Blum, Steven McCune, Timothy Pluard, Daniel Anderson, Eric Gauthier

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study.
Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Eric Gauthier

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.
Debu Tripathy, Joanne L Blum, Hong Zhang, Shibing Deng, Steven L McCune, Eric Gauthier

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.
Debu Tripathy, Joanne L Blum, Meghan S Karuturi, Steven McCune, Sobha Kurian, Eric Gauthier

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR/HER2 Advanced Breast Cancer in Real-World Settings.
Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Eric Gauthier

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.
Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Eric Gauthier

Breast Cancer Res Treat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Eric Gauthier

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss, Eric Gauthier

NPJ Breast Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Dennis J Slamon, Véronique Diéras, Hope S Rugo, Nadia Harbeck, Seock-Ah Im, Eric Gauthier

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Eric Gauthier

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Richard S Finn, Hope S Rugo, Karen A Gelmon, Massimo Cristofanilli, Marco Colleoni, Eric Gauthier

Oncologist· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Richard S Finn, Massimo Cristofanilli, Johannes Ettl, Karen A Gelmon, Marco Colleoni, Eric Gauthier

Breast Cancer Res Treat· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Hope S Rugo, Richard S Finn, Karen Gelmon, Anil A Joy, Nadia Harbeck, Eric Gauthier

Clin Breast Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of a cyanine dye assay for the evaluation of the biocompatibility of magnesium alloys by direct and indirect methods.
Afrah Al Hegy, Ryan Smith, Eric R Gauthier, Joy E Gray-Munro

Bioact Mater· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Eric Gauthier

Oncologist· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Eric Gauthier

JNCI Cancer Spectr· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
Richard S Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S Rugo, Eric Gauthier

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Véronique Diéras, Nadia Harbeck, Anil Abraham Joy, Karen Gelmon, Johannes Ettl, Eric Gauthier

Oncologist· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Eric Gauthier

J Glob Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Véronique Diéras, Hope S Rugo, Patrick Schnell, Karen Gelmon, Massimo Cristofanilli, Eric Gauthier

J Natl Cancer Inst· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Chandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, Xin Huang, Dongrui R Lu

Anticancer Drugs· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of mixed organosilane coatings with variable RGD surface densities on the adhesion and proliferation of human osteosarcoma Saos-2 cells to magnesium alloy AZ31.
Xiaoxi Yang, Afrah Al Hegy, Eric R Gauthier, Joy Gray-Munro

Bioact Mater· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Eric Gauthier

N Engl J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis